Advertisement
New Zealand markets close in 4 hours 11 minutes
  • NZX 50

    11,802.20
    -33.84 (-0.29%)
     
  • NZD/USD

    0.5899
    -0.0007 (-0.12%)
     
  • NZD/EUR

    0.5542
    -0.0003 (-0.05%)
     
  • ALL ORDS

    7,824.70
    -74.20 (-0.94%)
     
  • ASX 200

    7,568.40
    -73.70 (-0.96%)
     
  • OIL

    82.48
    -0.25 (-0.30%)
     
  • GOLD

    2,391.60
    -6.40 (-0.27%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     
  • NIKKEI 225

    37,358.92
    -720.78 (-1.89%)
     
  • NZD/JPY

    91.1830
    -0.0710 (-0.08%)
     

A CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 16% last year

Looking at CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

Check out our latest analysis for CASI Pharmaceuticals

CASI Pharmaceuticals Insider Transactions Over The Last Year

The Chairman & CEO Wei-Wu He made the biggest insider purchase in the last 12 months. That single transaction was for US$273k worth of shares at a price of US$3.18 each. That means that an insider was happy to buy shares at above the current price of US$1.99. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Wei-Wu He was the only individual insider to buy shares in the last twelve months.

ADVERTISEMENT

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, CASI Pharmaceuticals insiders have about 4.8% of the stock, worth approximately US$1.3m. However, it's possible that insiders might have an indirect interest through a more complex structure. We consider this fairly low insider ownership.

What Might The Insider Transactions At CASI Pharmaceuticals Tell Us?

It doesn't really mean much that no insider has traded CASI Pharmaceuticals shares in the last quarter. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more CASI Pharmaceuticals stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing CASI Pharmaceuticals. Our analysis shows 3 warning signs for CASI Pharmaceuticals (1 shouldn't be ignored!) and we strongly recommend you look at them before investing.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here